CA3235677A1 - Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance - Google Patents
Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance Download PDFInfo
- Publication number
- CA3235677A1 CA3235677A1 CA3235677A CA3235677A CA3235677A1 CA 3235677 A1 CA3235677 A1 CA 3235677A1 CA 3235677 A CA3235677 A CA 3235677A CA 3235677 A CA3235677 A CA 3235677A CA 3235677 A1 CA3235677 A1 CA 3235677A1
- Authority
- CA
- Canada
- Prior art keywords
- cbd
- asd
- subject
- irritability
- abc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271015P | 2021-10-22 | 2021-10-22 | |
| US63/271,015 | 2021-10-22 | ||
| PCT/US2022/078449 WO2023070045A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235677A1 true CA3235677A1 (en) | 2023-04-27 |
Family
ID=84358575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235677A Pending CA3235677A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240342198A1 (enExample) |
| EP (1) | EP4419091A1 (enExample) |
| JP (1) | JP2024536581A (enExample) |
| KR (1) | KR20240093852A (enExample) |
| CN (1) | CN118284412A (enExample) |
| AU (1) | AU2022373753A1 (enExample) |
| CA (1) | CA3235677A1 (enExample) |
| IL (1) | IL312328A (enExample) |
| MX (1) | MX2024004766A (enExample) |
| WO (1) | WO2023070045A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| WO2010127033A1 (en) | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| CA3300266A1 (en) * | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| WO2019224824A1 (en) * | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| JP7856584B2 (ja) * | 2020-05-26 | 2026-05-11 | ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド | カンナビジオールを用いた自閉症スペクトラム障害の処置 |
| TWI902836B (zh) * | 2020-06-29 | 2025-11-01 | 美商和諧生物科學管理股份有限公司 | 以大麻二酚(cannabidiol)治療X染色體脆折症候群 |
| LT4243797T (lt) * | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
-
2022
- 2022-10-20 CN CN202280077354.9A patent/CN118284412A/zh active Pending
- 2022-10-20 MX MX2024004766A patent/MX2024004766A/es unknown
- 2022-10-20 IL IL312328A patent/IL312328A/en unknown
- 2022-10-20 WO PCT/US2022/078449 patent/WO2023070045A1/en not_active Ceased
- 2022-10-20 KR KR1020247016925A patent/KR20240093852A/ko active Pending
- 2022-10-20 JP JP2024523674A patent/JP2024536581A/ja active Pending
- 2022-10-20 AU AU2022373753A patent/AU2022373753A1/en active Pending
- 2022-10-20 CA CA3235677A patent/CA3235677A1/en active Pending
- 2022-10-20 EP EP22803457.5A patent/EP4419091A1/en active Pending
-
2024
- 2024-04-22 US US18/642,059 patent/US20240342198A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024536581A (ja) | 2024-10-04 |
| CN118284412A (zh) | 2024-07-02 |
| WO2023070045A1 (en) | 2023-04-27 |
| MX2024004766A (es) | 2024-06-11 |
| IL312328A (en) | 2024-06-01 |
| US20240342198A1 (en) | 2024-10-17 |
| AU2022373753A1 (en) | 2024-05-09 |
| KR20240093852A (ko) | 2024-06-24 |
| EP4419091A1 (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226373B2 (en) | Treatment of fragile X syndrome with cannabidiol | |
| US20240342198A1 (en) | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance | |
| US12582664B2 (en) | Treatment of fragile x syndrome with cannabidiol | |
| JP7856584B2 (ja) | カンナビジオールを用いた自閉症スペクトラム障害の処置 | |
| US20260027137A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20250177322A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| HK40036001B (en) | Treatment of fragile x syndrome and autism with cannabidiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20241024 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241115 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241204 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250627 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251010 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260513 |